目的:探讨重组人血小板生成素(rhTPO)联合标准剂量糖皮质激素在治疗成人原发免疫性血小板减少症(ITP)方面的短期疗效及安全性。方法:选取2018年1月1日至2024年6月1期间北华大学附属医院血液科收治的93例ITP患者进行回顾性分析,根据治疗方法的不同,将患者分为研究组(46例)和对照组(47例),对照组患者给予标准剂量醋酸泼尼松片治疗,研究组患者在标准剂量醋酸泼尼松片基础上联合重组人血小板生成素治疗,比较两组患者治疗前及治疗后第3、7、14 d时PLT水平的变化情况、PLT增幅情况以及总有效率,观察药物的不良反应。结果:研究组与对照组治疗后的PLT与治疗前相比较,均高于治疗前水平,研究组在治疗后d14,PLT数值、较用药前PLT升高程度均显著高于对照组(P 0.05)。结论:重组人血小板生成素联合标准剂量糖皮质激素治疗原发免疫性血小板减少症的短期疗效较显著,可明显升高PLT计数,且安全性较好,不会出现严重的不良反应。Objective: Investigate the short-term therapeutic effect and safety of recombinant human thrombopoietin (rhTPO) in conjunction with standard-dose glucocorticoids for the treatment of adult primary immune thrombocytopenia (ITP). Method: A retrospective analysis was performed on 93 patients with immune thrombocytopenia (ITP) admitted to the Hematology Department of Affiliated Hospital of Beihua University from January 1, 2018 to June 1, 2024. They were separated into a study group with 46 cases and a control group containing 47 cases. Patients in the control group were given standard-dose prednisone acetate tablets, while patients in the study group were treated with recombinant human thrombopoietin in addition to standard-dose prednisone acetate tablets. The changes in platelet count (PLT) levels before treatment and on the 3rd, 7th, and 14th days after treatment, as well as platelet increase and total effective rate, were compared between the two groups. A
目的观察阿伐曲泊帕联合重组人血小板生成素(rhTPO)对恶性血液病自体造血干细胞移植(ASCT)后血小板(PLT)植入的临床疗效。方法回顾性分析76例ASCT患者的临床资料,其中40例阿伐曲泊帕(avatrombopag,AVA)联合rhTPO升血小板治疗为观察组,36例rhTPO单药治疗为对照组。比较两组患者PLT水平、PLT植入时间、PLT输注数量、PLT谷值及Ⅳ级血小板减少持续时间,记录不良反应。结果观察组PLT植入时间短于对照组[(11.15±1.08)d v s.(12.61±2.65)d,(P<0.05)],且PLT输注单位数少于对照组[2(1.00,2.75)U v s.3(2.00,4.00)U,(P<0.001)];阿伐曲泊帕联合rhTPO促血小板治疗的第5天、第10天、第15天,血小板计数均高于相应单药对照组,药物干预后的第5天及第10天血小板植入率有所提高(P<0.05)。多元线性回归分析显示,阿伐曲泊帕是影响PLT植入时间的独立因素(P<0.001),其使用可将植入时间缩短1.598天。两组患者均观察到出血事件,以皮肤黏膜出血点、瘀斑、牙龈出血为主,出血发生率无差异。两组均无血栓形成及凝血障碍发生。结论阿伐曲泊帕联合rhTPO能有效升高ASCT患者PLT计数,促进PLT植入,二者联用有协同作用,且耐受良好。
